


AMENDMENTS TO AND LISTING OF CLAIMS

1. (Currently amended) A compound of formula I




wherein

R_a is H[,] or C_{1-4} -alkyl, ~~or C_{1-4} -alkyl substituted by OH, NH_2 , NHC_{1-4} -alkyl or $N(di-C_{1-4}$ -alkyl) $_2$;~~

one of R_b , R_c , R_d and R_e is halogen, C_{1-4} -alkoxy, or C_{1-4} -alkyl, and the other three substituents are H; or R_b , R_c , R_d and R_e are all H; and

R is a radical of formula (a)



wherein

R_1 is $-(CH_2)_n-NR_3R_4$, wherein

each of R_3 and R_4 , independently, is H or C_{1-4} -alkyl; ~~or R_3 and R_4 form together with the nitrogen atom to which they are bound a heterocyclic residue;~~

n is 0, 1 or 2; and

R_2 is H, halogen, C_{1-4} -alkyl, CF_3 , OH, SH, NH_2 , or NO_2 , C_{1-4} -alkoxy, C_{1-4} -alkylthio, NHC_{1-4} -alkyl, $N(di-C_{1-4}$ -alkyl) $_2$ or CN;

or a salt thereof.

2. (Currently amended) A compound according to Claim 1, wherein R_a is H or methyl; one of R_b , R_c , R_d and R_e is methyl or ethyl and the other three substituents are H; or R_b , R_c , R_d and R_e are all H; R_2 is H, Cl, methyl or NO_2 ; n is 1; and each of R_3 and R_4 ,

independently, is H, methyl, ethyl or *i*-propyl; ~~or R₃ and R₄ form together with the nitrogen atom to which they are bound, a heterocyclic residue, or a salt thereof.~~

3. (Currently amended) A compound according to Claim 1, which is selected from 3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro 6-methylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;
3-(6-Aminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-methylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(6-Aminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;
3-(6-Aminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione; ~~or~~
and a salt of any thereof.

4. (Currently amended) A compound according to Claim 1, in free form or in a pharmaceutically-acceptable salt form, for use as a pharmaceutical.


5. and 6. (Canceled)

7. (Withdrawn by the Examiner) Use of a compound according to claim 1, in free form or in a pharmaceutically acceptable salt form, or a pharmaceutical composition according to claim 5 in the manufacture of a medicament for treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection, cancer or infectious diseases.


8. (Currently amended) A pharmaceutical combination comprising a compound according to Claim 1, in free form or in a pharmaceutically-acceptable salt form, and a

further agent selected from immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic, antiproliferative and anti-diabetic agents.

9. (Currently amended) A process for the production of the compound of formula I according to Claim 1, which process comprises reacting a compound of formula II



wherein R_a, R_b, R_c, R_d and R_e are as defined in Claim 1,
with a compound of formula III



wherein R is as defined in Claim 1 ~~and claim 2~~,
and, where required, converting the resulting compound of formula I obtained in free form to a salt form or *vice versa*, as appropriate.

10. (Withdrawn by the Examiner) A method for treating or preventing disorders or diseases mediated by T lymphocytes and/or PKC, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.